Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
DUBLIN - Morgan Stanley Capital Services LLC has disclosed its recent trading activity in Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares, according to a regulatory filing submitted Monday.
The filing, made under the Irish Takeover Panel Act rules, reveals that Morgan Stanley Capital Services, acting as an exempt principal trader with recognized intermediary status, purchased 129 ordinary shares of Avadel Pharmaceuticals on November 28, 2025. The shares were acquired at prices ranging from $21.45 to $21.49 per share.
On the same day, the firm sold 196 Avadel ordinary shares at $21.4769 per share, according to the disclosure.
The filing indicates that Morgan Stanley Capital Services is connected to Avadel Pharmaceuticals in relation to an unspecified offer. No cash-settled derivative transactions, stock-settled derivative transactions, or other dealings were reported in the disclosure.
The company confirmed it has no indemnity arrangements, options, agreements, or understandings relating to relevant securities that might influence trading decisions.
The disclosure was made in compliance with Rule 38.5(a) of the Irish Takeover Panel Act, which requires connected exempt principal traders to report dealings in relevant securities during offer periods.
Avadel Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medications for central nervous system disorders.
The information was provided through a regulatory news service filing with the London Stock Exchange.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.